Sydney Weiss

Sydney Weiss

Senior AI Reviewer

Sydney runs the lifecycle desk — re-checks, Graveyard entries, and the unglamorous work of catching silent price hikes. She came to ToolDirectory.AI from a research role at a developer-tools company, so the engineering and infra categories tend to land on her desk first. Writes the quarterly "state of AI X" essays you may have seen on the blog.

Recent reviews by Sydney Weiss
Adcreative.ai
Adcreative.ai
4.20

Fast ad and social creative generation that handles the boring iteration work, though quality varies by brief specificity. Owned by Appier since March 2025.

Read review →
Niantic Labs
Niantic Labs
3.50

Scopely bought Niantic's games division for $3.5B in May 2025, taking Pokémon GO with it. The remaining company, still led by founder John Hanke, is now Niantic Spatial and builds geospatial AI rather than games.

Read review →
NotebookLM
NotebookLM
4.70

Renamed Gemini Notebook in July 2026, and the rename carried substance: every notebook now gets a secure cloud computer, so it analyses and builds rather than only summarising. Still the best source-grounded research tool. Google’s pricing maze is the weak point.

Read review →
Google Flow
Google Flow
4.10

Google’s filmmaking studio treats the sequence, not the clip, as the unit of work — Scenebuilder continuity, deliberate first and last frame control, and audio generated with the footage. Now running Gemini Omni, Veo 3.1, and Nano Banana, with a daily free allowance.

Read review →
Meshy
Meshy
4.20

Meshy 6 moved this from novelty to pipeline tool: cleaner topology, meshes into the hundreds of thousands of faces, and a low poly mode aimed at real game budgets. Licensing is tiered, so check which plan grants the rights you need before shipping assets.

Read review →
Doximity GPT
Doximity GPT
4.40

Free, HIPAA-compliant clinical AI from the network most US physicians already use, now renamed Doximity Ask. Answers arrive conclusion-first and pass through a review programme staffed by more than 12,000 physician editors. The catch is access: verified US clinicians only.

Read review →

Sign up for our newsletter

Receive weekly updates so you can stay up-to-date with the world of AI